BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19167214)

  • 41. Current immunotherapeutic strategies in colon cancer.
    Morse M; Langer L; Starodub A; Hobeika A; Clay T; Lyerly HK
    Surg Oncol Clin N Am; 2007 Oct; 16(4):873-900, x. PubMed ID: 18022550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
    Fry TJ; Lankester AC
    Pediatr Clin North Am; 2008 Feb; 55(1):147-67, xi. PubMed ID: 18242319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
    Grange JM; Krone B; Stanford JL
    Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): moving forward.
    Malyguine A; Umansky V; Kotlan B; Aptsiauri N; Shurin MR
    J Immunotoxicol; 2012; 9(3):231-5. PubMed ID: 22639903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-idiotype antibodies in cancer treatment.
    de Cerio AL; Zabalegui N; Rodríguez-Calvillo M; Inogés S; Bendandi M
    Oncogene; 2007 May; 26(25):3594-602. PubMed ID: 17530013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting cancer therapy.
    Begent RH
    Br J Cancer; 1999 Jul; 80 Suppl 1():104-9. PubMed ID: 10466768
    [No Abstract]   [Full Text] [Related]  

  • 49. Cancer vaccines: pessimism in check.
    Timmerman JM; Levy R
    Nat Med; 2004 Dec; 10(12):1279; author reply 1279-80. PubMed ID: 15682512
    [No Abstract]   [Full Text] [Related]  

  • 50. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.
    Croix BS
    Cytotherapy; 2007; 9(1):1-3. PubMed ID: 17354097
    [No Abstract]   [Full Text] [Related]  

  • 51. Advances in prophylactic cancer vaccine research.
    Le Poole IC; Bommiasamy H; Bocchetta M; Kast WM
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):537-45. PubMed ID: 12934665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multipeptide vaccination in cancer patients.
    Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overcoming technical challenges in the development of cancer vaccines.
    Dalgleish A
    IDrugs; 2007 Jul; 10(7):463-7. PubMed ID: 17642016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peptide-based vaccines for cancer: realizing their potential.
    Kanodia S; Kast WM
    Expert Rev Vaccines; 2008 Dec; 7(10):1533-45. PubMed ID: 19053209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes.
    Pashov A; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2009 May; 27(25-26):3405-15. PubMed ID: 19200843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor microenvironment and the immune response.
    Selleri S; Rumio C; Sabatino M; Marincola FM; Wang E
    Surg Oncol Clin N Am; 2007 Oct; 16(4):737-53, vii-viii. PubMed ID: 18022542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological approaches to cancer treatment.
    Murgo AJ
    W V Med J; 1989 Jun; 85(6):233-8. PubMed ID: 2735012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.